从注射药物转换为其他疾病修饰疗法可能会改善多发性硬化症患者的性功能障碍
Sara Ala1, Ali Amirkafi2, Kosar Kohandel1
1Multiple Sclerosis Research Center,Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
BMC neurology
|July 25, 2024
概括
切换多发性硬化症 (MS) 药物改善了女性的性功能,特别是MSISQ-19问卷的第三级领域. 其他性功能障碍领域在六个月后没有显著变化.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 性医学性医学性医学性医学
背景情况:
- 多发性硬化症 (MS) 是一种中枢神经系统自身免疫性疾病,影响年轻人,女性更常见.
- 多发性硬化可以在两性中引起性功能障碍 (SD),包括疼痛,欲望低下和兴奋/高潮问题.
- 女性SD包括失恋症,性欲缺乏,以及兴奋和高潮阶段的障碍.
研究的目的:
- 为了研究从注射疗法转换为新药后,MS女性的性功能变化.
- 在六个月内评估性功能障碍 (SD) 三个领域的变化.
主要方法:
- 一项纵向研究包括107名患有多发性硬化症的女性 (18-50岁) 从干扰素β-1a或格拉提拉乙酸转换为芬戈利莫德,二甲基酸盐或纳塔利祖马布.
- 多发性硬化症亲密性和性质问卷-19 (MSISQ-19) 评估了多发性硬化症在治疗转换前和六个月后的SD.
- 由于定量变量的非正常分布,统计分析使用了Wilcoxon签名等级测试.
主要成果:
- 药物转换后,MSISQ-19总体得分没有显著变化 (p=0.091).
- 在MSISQ-19的三级子域中观察到显著的改善 (p=0.017).
- 主要 (p=0.761) 和次要 (p=0.479) SD域,以及EDSS得分 (p=0.461) 没有显著变化.
结论:
- 这项研究是首次评估MS药物改变对SD的影响.
- 切换多发性硬化药物导致性功能的第三级领域显著改善.
- 在六个月的研究期间,在其他SD领域或EDSS分数中没有发现显著变化.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
Drug Delivery: Miscellaneous Routes
335
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
335
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110


